
FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone
The FDA’s Antimicrobial Drugs Advisory Committee voted 14-1 in favor of a limited-use indication for Cidara Therapeutics’ rezafungin, a treatment for candidemia and invasive candidiasis.
According to Cidara on Wednesday, the vote was based on data from two trials run by Cidara, with a once-weekly dose of rezafungin demonstrating statistical non-inferiority versus caspofungin, the current standard.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.